A new study suggests that Medicare could save up to $366 million annually by introducing a new vial size for Alzheimer’s drug lecanemab, which is currently only available in single-use, 500- and 200-milligram vials.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
